- Alexion Pharmaceuticals (NASDAQ:ALXN) files a marketing application with the Japanese Ministry of Health, Labour and Welfare seeking approval of Soliris (eculizumab) for the treatment of patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive (AChR-positive), an ultra-rare population. There are currently no approved therapies for the condition.
- Patients with AChR-positive refractory gMG have difficulty walking, talking, swallowing and breathing. Exacerbations can be life-threatening and require hospitalization and intensive care.